Search PubMed⌕ Search

Biomedical subjects

T Nemoto

Publications and source records attributed to T Nemoto.

At least 253 records · Page 14Linked to original sources
PubMed1985

Dietary fat consumption and survival among women with breast cancer.

An historical prospective study was conducted to examine the relationship of dietary fat intake to disease progression and length of survival of 953 women with breast cancer. Estimates of monthly fat intake were based on patient responses about usual frequency of consuming 33 foods and beverages prior to symptom onset. Average estimated monthly fat intake did not vary by stage of disease at diagnosis. When controlling for disease stage and patient age at diagnosis, the estimated risk of death at any time increased 1.4-fold for each 1,000 g in monthly fat intake. Separate analysis by disease stage showed this association to be most pronounced for subjects with advanced disease. The need for future studies to incorporate clinical and pathologic factors in the analysis, to distinguish between sources of dietary fat intake, and to ascertain dietary patterns subsequent to breast cancer diagnosis was noted.

Adult↗
PubMed1985

Demonstration and characterization of cytosol androgen receptor in rat exorbital lacrimal gland.

The presence of a macromolecule which binds androgen with a high affinity and a low capacity was demonstrated in the cytosol of the lacrimal glands of male and female rats. Evidence was found that this macromolecule was a protein by treatment with protease, trypsin or heat. A specific 8-8.5 S peak was obtained in both sexes by glycerol gradient centrifugation in low salt condition, whereas a specific 5.2 S peak was found in high salt condition. This protein could bind to DNA-cellulose after treatment of androgen-cytosol complexes by warming (25 degrees C 15 min) or exposure under high salt (0.4 M KCl). These results suggested that this protein was an androgen receptor.

Animals↗
PubMed1985

Dialysis-induced transformation of mouse submandibular androgen-receptor.

Dialysis induced transformation of cytosol androgen receptor from mouse submandibular gland. On DEAE-Sephacel chromatography, this dialyzed [3H]methyltrienolone receptor complex was eluted at 0.10 M KCl which was lower than 0.25 M KCl required to elute the nontransformed androgen receptor complex, but higher than 0.05 M KCl required to elute the heat transformed receptor. On glycerol density gradient centrifugation, the dialysis transformed receptor complex shifted its sedimentation coefficient to 6 S from 8 S of the nontransformed condition, whereas the heat transformed receptor was sedimented at 4 S. Molybdate inhibited the dialysis-induced transformation on DEAE-Sephacel chromatography. The charge and the molecular size of dialysis-induced transformed receptor complex were different from those of heat-induced transformed receptor complex.

Animals↗
PubMed1985

Conversion from 4S androgen receptor from rat submandibular gland to higher molecular form and the effect of sodium molybdate.

The androgen receptor from rat submandibular gland was transformed by exposure to ATP at 0 degrees C. The transformed 4 S receptor converted to a higher molecular weight form in a low-salt glycerol gradient centrifugation when ATP was removed from the sample. The sedimentation coefficient of the converted receptor was similar in the absence or presence of 20 mM molybdate; 7.8 +/- 0.5 S without molybdate and 7.6 +/- 0.3 S with molybdate. However, the receptor converting in the presence of molybdate could markedly bind to DNA-cellulose, while an entity without molybdate could not. These results suggest that molybdate directly interacts with the DNA-binding domain on the 4 S androgen receptor and prevents this domain from being concealed by conversion in low-salt conditions.

Adenosine Triphosphate↗
PubMed1984

Binding of [3H]methyltrienolone to androgen receptor in rat liver.

The synthetic androgen methyltrienolone is superior to testosterone and androstenedione for the measurement of androgen receptor in tissues where the native ligands are metabolized into inactive derivatives. [3H]Methyltrienolone binds with a high affinity to androgen receptor in cytosol prepared from male rat livers, as the Scatchard analysis revealed that the Kd value was 3.3 X 10(-8) M and the number of binding sites was 35.5 fmol/mg protein. Since methyltrienolone also binds glucocorticoid receptor which exists in rat liver, the apparent binding of androgen receptor is faulty when measured in the presence of glucocorticoid receptor. The binding of methyltrienolone to glucocorticoid receptor can be blocked by the presence of a 100-fold molar excess of unlabeled synthetic glucocorticoid, triamcinolone acetonide, without interfering in its binding to androgen receptor, because triamcinolone does not bind to androgen receptor. Triamcinolone-blocked cytosol exhibited that the Kd value was 2.5 X 10(-8) M and the number of binding sites was 26.3 fmol/mg protein, indicating a reduction to 3/4 of that in the untreated cytosol. The profile of glycerol gradient centrifugation indicated that [3H]methyltrienolone-bound receptor migrated in the 8-9 S region in both untreated and triamcinolone-blocked cytosols, but the 8-9 S peak in triamcinolone-blocked cytosol was reduced to about 3/4 of that of untreated cytosol.

Animals↗
PubMed1984

Activation of the rat liver androgen-receptor complex.

Activation of androgen receptor in rat liver cytosol was studied in vitro. The state of activation was judged by binding of [3H] R1881-receptor complex to chromatin. High ionic strength (0.4 M KCl as a final concentration) provoked the binding of [3H] R1881-receptor complex to chromatin at 0 degrees C. At low ionic strength, activation was very slow at 0 degrees C, but was very rapid at 25 degrees C and reached the maximum at 15 min of heating.

Animals↗
PubMed1984

Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer.

The relative efficacy of adrenalectomy and tamoxifen (Nolvadex) was evaluated in a randomized study of 51 patients with metastatic breast cancer. In 25 patients undergoing adrenalectomy, there were 13 responders. There were 9 responders of 26 patients receiving tamoxifen. There was no statistically significant difference. In the crossover phase, 15 patients received tamoxifen following adrenalectomy and 3 responded, one of the 6 previous adrenalectomy responders and 2 of the 9 adrenalectomy nonresponders. Nine patients underwent adrenalectomy following tamoxifen, and there were five responders, one of two tamoxifen responders and four of seven tamoxifen nonresponders. Both tamoxifen and adrenalectomy were effective modalities, and appear to retain effectiveness in crossover trials. The frequency of remission was similar in both groups treated by both modalities in different sequences. Response rates to adrenalectomy, considered as both primary and secondary therapy, were significantly higher, since 18 of 34 patients (53%) responded to this therapy, whereas 12 of 41 (29%) responded to tamoxifen as either primary or secondary therapy.

Adrenalectomy↗
PubMed1984

Metastatic breast cancer in males. Assessment of endocrine therapy.

From June 1958 to June 1982, 22 men with metastatic breast cancer were treated with endocrine therapy. All 22 patients were initially treated by bilateral orchiectomy, and objective response was seen in 11 (50%) patients for 15 months. Bilateral adrenalectomy was performed subsequently in 10 patients, and 8 (80%) patients had a mean duration of objective response of 15 months. Five of seven orchiectomy responders and 3 of 3 orchiectomy nonresponders subsequently responded to bilateral adrenalectomy. Tamoxifen was tried in three patients after relapse following adrenalectomy; all three patients responded with a mean duration of 9 months. One patient was successfully treated with aminoglutethimide for 7 months following orchiectomy failure. In this patient bilateral adrenalectomy was performed on disease relapse and again resulted in objective remission. In this review, a sequential endocrine therapy program provided palliation in men. Further study is required to determine the timing of the various endocrine modalities.

Adrenalectomy↗
PubMed1984

Expression of ductal carcinoma antigen in breast cancer sera as defined using monoclonal antibody F36/22.

A quantitative immunoassay procedure has been constructed to evaluate levels of ductal carcinoma antigen recognized by murine McAb F36/22. Using this method, 3% of 64 apparently healthy individuals and 13% of 40 patients with benign breast disease expressed serum antigen levels above 70 units/ml. Greater than 50% of 116 patients with clinical evidence of breast cancer demonstrated circulating ductal carcinoma antigen levels above 70 units/ml. Patients with ductal carcinomas of other sites, including prostate and gastrointestinal tumors, also demonstrated elevated levels of antigen (11 and 27%, respectively). The incidence of elevated serum ductal carcinoma antigen levels correlated significantly with the incidence of intratumoral antigen expression. Lectin binding, molecular weight, and density measurements indicated that circulating antigen occurs as a high-molecular-weight glycoprotein with mucin-like characteristics.

Antibodies, Monoclonal↗